Beijing Biostar Pharmaceuticals (2563) Stock Overview
A synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
2563 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Beijing Biostar Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.96 |
| 52 Week High | HK$39.50 |
| 52 Week Low | HK$4.28 |
| Beta | 0 |
| 1 Month Change | 11.17% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.92% |
Recent News & Updates
Shareholder Returns
| 2563 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.0% | 6.4% | 0.4% |
| 1Y | n/a | 191.9% | 45.9% |
Return vs Industry: Insufficient data to determine how 2563 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2563 performed against the Hong Kong Market.
Price Volatility
| 2563 volatility | |
|---|---|
| 2563 Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.8% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2563's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2563's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 131 | Rongguo Qiu | www.biostar-pharm.com |
Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of advanced and neoadjuvant breast cancer, advanced non-small cell lung cancer, gastric and esophageal cancer, brain metastasis, solid tumors, and glioblastoma. It is also involved in the development of Utidelone capsule that is in Phase II/III clinical trials; Utidelone nanoformulation; and Utidelone antibody drug conjugate, as well as other active pharmaceutical ingredients, such as BG22, BG18, and BG44 in early development stages.
Beijing Biostar Pharmaceuticals Co., Ltd. Fundamentals Summary
| 2563 fundamental statistics | |
|---|---|
| Market cap | HK$1.94b |
| Earnings (TTM) | -HK$139.06m |
| Revenue (TTM) | HK$58.49m |
Is 2563 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2563 income statement (TTM) | |
|---|---|
| Revenue | CN¥53.53m |
| Cost of Revenue | CN¥7.03m |
| Gross Profit | CN¥46.50m |
| Other Expenses | CN¥173.76m |
| Earnings | -CN¥127.26m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 86.87% |
| Net Profit Margin | -237.73% |
| Debt/Equity Ratio | 0.09% |
How did 2563 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/06 14:56 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Biostar Pharmaceuticals Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhishun Siu | CCB International Securities Limited |